Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
03/2005
03/31/2005US20050070719 Central nervous system disorders; antidiabetic agents; antiinflammatory agents; antiarthritic agents;obesity; osteoporosis ; anticancer agents
03/31/2005US20050070718 Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
03/31/2005US20050070713 Neurokinin antagonist; therapy for central nervous system disorders; psychological disorders; Parkinson's and Huntington's disease
03/31/2005US20050070706 Antidiabetic agents; obesity; controlling appetite
03/31/2005US20050070589 Pyrazolyl inhibitors of 15- lipoxygenase
03/31/2005US20050070588 Imidazolyl inhibitors of 15-lipoxygenase
03/31/2005US20050070581 such as 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxybenzylidene-2,4-thiazolidinedione; Hodgkin's disease
03/31/2005US20050070575 Such as N6-[6-(2-dimethylaminoethylamino)-4-methylsulfanyl-[1,3,5]triazin-2-yl]-2-methylquinoline-4,6-diamine, which stabilizes DNA in G-quadruplex structures (guanine tetrads); anticancer agents
03/31/2005US20050070574 Novel compounds
03/31/2005US20050070573 e.g., 6-chloro-2-methyl-4-(N-(2-(N-(p-methoxyphenylsulfonyl)-N-(2-(2,5-dimethoxy-4-nitroanilinocarbonyl)ethyl)amino)ethyl)amino)quinoline; used to treat inflammatory and immune diseases by binding to CXCR3 receptors.
03/31/2005US20050070571 Such as N6-[6-(2-dimethylaminoethylamino)-4-methylsulfanyl-[1,3,5]triazin-2-yl]-2-methylquinoline-4,6-diamine, which stabilizes DNA in G-quadruplex structures (guanine tetrads); anticancer agents
03/31/2005US20050070562 Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
03/31/2005US20050070561 For example, 2-(3-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-yl]amino}-1H-pyrazol-5-yl)-N-phenylacetamide; use in the treatment of certain diseases, in particular to proliferative disease such as cancer
03/31/2005US20050070550 Benzoimidazole compounds
03/31/2005US20050070549 heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation
03/31/2005US20050070547 Useful in treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals; for treating conditions responsive to capsaicin receptor modulation, such as pain, itch, urinary incontinence, overactive bladder, cough, hiccup
03/31/2005US20050070546 Tyrosine kinase inhibitors
03/31/2005US20050070535 Antidiabetic agents; obesity; controlling appetite
03/31/2005US20050070534 Non-peptidic NPY Y2 receptor inhibitors
03/31/2005US20050070531 Using such as 2-[2-(3-Amino-piperidin-1-yl)4-oxo-4H-quinazolin-3-ylmethyl]-benzonitrile to treat cancer and/or autoimmune disorder
03/31/2005US20050070530 Dipeptidyl peptidase inhibitors
03/31/2005US20050070523 For therapy of bacterial infection in a mammal
03/31/2005US20050070520 Aza-cyclic compounds as modulators of acetylcholine receptors
03/31/2005US20050070439 Tetrazoyl oxime derivative and agricultural chemical containing the same as active ingredient
03/31/2005US20050069555 Vaccine adjuvants; hepatitis c virus; modulation immunology response
03/31/2005CA2808646A1 Thalidomide analogs
03/31/2005CA2551037A1 Novel piperidine derivative
03/31/2005CA2539766A1 Benzimidazole derivates: preparation and pharmaceutical applications
03/31/2005CA2539566A1 Benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors
03/31/2005CA2538864A1 Thalidomide analogs as tnf-alpha modulators
03/31/2005CA2538855A1 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
03/31/2005CA2538591A1 Synthesis of quinoline 5-carboxamides useful for the preparation of pde iv inhibitors
03/31/2005CA2538590A1 Novel gamma secretase inhibitors
03/31/2005CA2538381A1 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)
03/30/2005EP1519192A2 HIV Protease inhibitor conjugates and antibodies useful in ummunoassay
03/30/2005EP1518857A1 A process for the preparation of pantoprazole and salts thereof
03/30/2005EP1518856A1 Process for producing quinolonecarboxylic acid derivative
03/30/2005EP1518855A1 Diaminopyrimidinecarboxa mide derivative
03/30/2005EP1517905A1 Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases
03/30/2005EP1517904A2 Mitotic kinesin inhibitors
03/30/2005EP1517903A2 Marked maleimide compounds, method for preparing same and use thereof for marking macromolecules
03/30/2005EP1517898A1 Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
03/30/2005EP1517896A2 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity
03/30/2005EP1517895A1 8-(biaryl) quinoline pde4 inhibitors
03/30/2005EP1517690A1 Liquid dosage forms of non-enterically coated acid-labile drugs
03/30/2005EP1446496A4 Methods for ligand discovery
03/30/2005EP1360184B1 Piperidine derivatives as neurokinin 1 antagonists
03/30/2005EP1264826B1 Novel imidazoline compounds
03/30/2005EP1075467B1 Pyrazole derivatives as p-38 map kinase inhibitors
03/30/2005CN1602344A Electroluminescent platinum compounds and devices made with such compounds
03/30/2005CN1602206A Pharmaceutical compositions based on azetidine derivatives
03/30/2005CN1602195A Quinazoline derivatives for the treatment of abnormal cell growth
03/30/2005CN1602191A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
03/29/2005US6872851 Melatonergic receptors; antiinflammatory agents; anticancer agents
03/29/2005US6872837 Taxanes having a c10 Heterosubstituted acetate substituent
03/29/2005US6872834 Phenyl-substituted indoles and indazoles
03/29/2005US6872746 Isomeric fused pyrrolocarbazoles and isoindolones
03/29/2005US6872745 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
03/29/2005US6872733 Benzimidazolone compounds
03/29/2005US6872728 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
03/29/2005US6872726 Fluorinated di-aryl urea compounds
03/29/2005US6872725 Crystallized p38 kinase inhibitors for treatment of rheumatoid arthritis
03/29/2005US6872717 Pharmacological uses of azetidine derivatives
03/29/2005US6872716 Sexual diosrders; schizophrenia; drug abuse; eating disorders anxiolytic agents
03/29/2005US6872714 Methods to modulate conditions mediated by the CXCR4 receptor
03/29/2005US6872690 Spraying on plants, environment
03/29/2005CA2260213C Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
03/29/2005CA2102750C Substituted triazolinones
03/24/2005WO2005026165A1 Quinolone antibacterial agents
03/24/2005WO2005026161A1 Antibacterial agents
03/24/2005WO2005026156A1 Quinazoline derivatives
03/24/2005WO2005026155A1 Benzimidazole acetonitriles
03/24/2005WO2005026152A1 Quinazoline derivatives as antitumor agents
03/24/2005WO2005026151A1 Quinazoline derivatives as tyrosine kinase inhibitors
03/24/2005WO2005026150A1 Quinazoline derivatives as tyrosine kinase inhibitors
03/24/2005WO2005026149A1 Pyrrol derivatives with antibacterial activity
03/24/2005WO2005026148A1 Dipeptidyl peptidase inhibitors
03/24/2005WO2005026147A1 7-(4-substituted 3- cyclopropylaminomethyl-1­ pyrrolidinyl) quinolonecarboxylic acid derivative
03/24/2005WO2005026146A1 Azetidinyl quinolones as antibacterial agents
03/24/2005WO2005026145A2 Quinolone antibacterial agents
03/24/2005WO2005026131A1 Transition state structure and inhibitors of thymidine phosphorylases
03/24/2005WO2005026130A1 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
03/24/2005WO2005026129A1 Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
03/24/2005WO2005026128A1 Ophthalmic compositions for treating ocular hypertension
03/24/2005WO2005026124A1 2-pyridone derivatives as netrophil elastase inhibitors and their use
03/24/2005WO2005026123A1 2-pyridone derivatives as neutrophil elastase inhibitors and their use
03/24/2005WO2005026114A1 Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses
03/24/2005WO2005025681A2 A system for and a method of manufacturing personal golf putters
03/24/2005WO2005025579A1 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
03/24/2005WO2005025576A1 7-heteroarylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents
03/24/2005WO2005025572A1 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
03/24/2005WO2005025556A2 Antibiotic cycloalkyltetrahydroquinoline derivatives
03/24/2005WO2005025555A2 Combinations of an aryl aniline beta-2 adrenergic receptor agonist and a corticosteroid
03/24/2005WO2005025507A2 Dihydropyridine compounds for treating or preventing metabolic disorders
03/24/2005WO2005025293A2 Fused ring heterocycles as potassium channel modulators
03/24/2005WO2005009967A3 Quinolinone derivatives as inhibitors of c-fms kinase
03/24/2005WO2005007648A3 Biaryl piperazinyl-pyridine analogues
03/24/2005WO2005003101A3 Pyrazine and pyridine derivatives as rho kinase inhibitors
03/24/2005WO2004111193A3 Prodrugs of mitotic kinesin inhibitors
03/24/2005WO2004096135A3 Inhibitors of akt activity
1 ... 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 ... 1080